Invitae's PCM Assay for Minimal Residual Disease Receives its First Commercial Coverage

  Invitae (NYSE: NVTA), a leading medical genetics company, today announced that its Personalized Cancer Monitoring (PCM™) assay, which helps detect minimal residual disease (MRD) in patients, has obtained its first commercial coverage in all solid tumors by Blue Shield of California. The policy, effective as of March 1, 2023, considers the test medically necessary for patients with stage I-IV cancer after surgical intervention for adjuvant or targeted therapy and/or monitoring for relapse or progression. 

https://www.biospace.com/article/releases/invitae-s-pcm-assay-for-minimal-residual-disease-receives-its-first-commercial-coverage/